Last month, IceCure Medical’s tumor-freezing technology won FDA approval for treating early-stage breast cancer. Now, the Israel-based medtech is touting a new study showing its procedure combined ...

Amtagvi monotherapy achieved a 25.6% objective response rate and 71.8% disease control rate in NSCLC patients without ...

The use of immunotherapy in patients with various types of cancer has led to dramatic increases in survival. Increased median ...

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical ...

October brought several updates in the lung cancer field, ranging from notable trial results to patient-centered perspectives ...

Results from a phase 1/2 clinical trial (NCT05099172) show the safety and efficacy of sevabertinib (BAY2927088) in patients ...

University of Queensland researcher Arutha Kulasinghe studied lung biopsies from the tumours of almost 250 patients with ...

According to the latest statistics from the Ministry of Data and Statistics, 21.9% of cancer-related deaths are attributed to ...

Stereotactic ablative radiotherapy (SABR) offers patients with early-stage non-small cell lung cancer (NSCLC) an effective alternative to the standard of care surgery — with significantly fewer severe ...

A new study finds that combining the COVID vaccine with immunotherapy may nearly double cancer survival rates — patients ...

Thanks to recent therapy advances, the lung cancer mortality rate has declined and survival rates have improved. Many factors influence the likelihood of a lung cancer cure or long-term survival, ...

Yes, lung cancer can be curable — if it’s found early and responds well to treatment. Thanks to recent therapy advances, the lung cancer mortality rate has declined and survival rates have improved.